James R. Eshleman

57.3k total citations · 9 hit papers
201 papers, 17.6k citations indexed

About

James R. Eshleman is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, James R. Eshleman has authored 201 papers receiving a total of 17.6k indexed citations (citations by other indexed papers that have themselves been cited), including 95 papers in Oncology, 85 papers in Cancer Research and 72 papers in Molecular Biology. Recurrent topics in James R. Eshleman's work include Cancer Genomics and Diagnostics (79 papers), Genetic factors in colorectal cancer (49 papers) and Pancreatic and Hepatic Oncology Research (42 papers). James R. Eshleman is often cited by papers focused on Cancer Genomics and Diagnostics (79 papers), Genetic factors in colorectal cancer (49 papers) and Pancreatic and Hepatic Oncology Research (42 papers). James R. Eshleman collaborates with scholars based in United States, Taiwan and Netherlands. James R. Eshleman's co-authors include Ralph H. Hruban, C. Richard Boland, David Sidransky, Stephen N. Thibodeau, Guglielmina Nadia Ranzani, Riccardo Fodde, Miguel A. Rodrı́guez-Bigas, Randall W. Burt, Stephen J. Meltzer and Sudhir Srivastava and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

James R. Eshleman

198 papers receiving 17.3k citations

Hit Papers

A National Cancer Institute Workshop on Microsatellite In... 1998 2026 2007 2016 1998 2010 2003 2009 2016 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.
    1998 3.3k citations David Sidransky, James R. Eshleman et al. profile →
  2. Distant metastasis occurs late during the genetic evolution of pancreatic cancer
    2010 1.8k citations Ralph H. Hruban, James R. Eshleman et al. profile →
  3. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours
    2003 1.0k citations Anirban Maitra, Antony R. Parker et al. profile →
  4. DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer
    2009 799 citations Christine A. Iacobuzio–Donahue, John L. Cameron et al. Journal of Clinical Oncology profile →
  5. Microsatellite Instability as a Biomarker for PD-1 Blockade
    2016 674 citations James R. Eshleman et al. Clinical Cancer Research profile →
  6. Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene
    2009 565 citations Ralph H. Hruban, Michael Borges et al. profile →
  7. Recurrent GNAS Mutations Define an Unexpected Pathway for Pancreatic Cyst Development
    2011 562 citations Jian Wu, Hanno Matthaei et al. Science Translational Medicine profile →
  8. PD-1 blockade in tumors with mismatch repair deficiency.
    2015 339 citations Brandon Luber, James R. Eshleman et al. Journal of Clinical Oncology profile →
  9. Haploinsufficiency of t e lomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita
    2005 324 citations James R. Eshleman et al. Proceedings of the National Academy of Sciences profile →

Peers

James R. Eshleman
Darryl Shibata United States
David G. Huntsman Canada
Michael F. Berger United States
G. Johan A. Offerhaus Netherlands
Jin Jen United States
J. Milburn Jessup United States
Kathleen R. Cho United States
Ann D. Thor United States
Heinz Höfler Germany
Manuel Perucho United States
Darryl Shibata United States
James R. Eshleman
Citations per year, relative to James R. Eshleman James R. Eshleman (= 1×) peers Darryl Shibata

Countries citing papers authored by James R. Eshleman

Since Specialization
Citations

This map shows the geographic impact of James R. Eshleman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James R. Eshleman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James R. Eshleman more than expected).

Fields of papers citing papers by James R. Eshleman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James R. Eshleman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James R. Eshleman. The network helps show where James R. Eshleman may publish in the future.

Co-authorship network of co-authors of James R. Eshleman

This figure shows the co-authorship network connecting the top 25 collaborators of James R. Eshleman. A scholar is included among the top collaborators of James R. Eshleman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James R. Eshleman. James R. Eshleman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chianchiano, Peter, Jacob T. Mitchell, Ludmila Danilova, et al.. (2025). Spatial profiling of human pancreatic ductal adenocarcinoma reveals molecular alterations associated with venous invasion. Science Translational Medicine. 17(817). eady7524–eady7524.
2.
Halper‐Stromberg, Eitan, Alyza Skaist, Hirohiko Kamiyama, et al.. (2024). CRISPR-Cas9 for selective targeting of somatic mutations in pancreatic cancers. NAR Cancer. 6(2). zcae028–zcae028. 3 indexed citations
3.
Lee, Su-Chan, Cornelia Peterson, Kaixuan Wang, et al.. (2024). Establishment and Characterization of Three Human Ocular Adnexal Sebaceous Carcinoma Cell Lines. International Journal of Molecular Sciences. 25(18). 10183–10183. 1 indexed citations
4.
Dbouk, Mohamad, Takeichi Yoshida, Kanako Yoshida, et al.. (2024). Using Tumor Marker Gene Variants to Improve the Diagnostic Accuracy of DUPAN-2 and Carbohydrate Antigen 19-9 for Pancreatic Cancer. Journal of Clinical Oncology. 42(18). 2196–2206. 17 indexed citations
5.
Knútsdóttir, Hildur, Fatemeh Shojaeian, Michael G. Lerner, et al.. (2023). Morphology-guided transcriptomic analysis of human pancreatic cancer organoids reveals microenvironmental signals that enhance invasion. Journal of Clinical Investigation. 133(8). 14 indexed citations
6.
Dbouk, Mohamad, Toshiya Abe, Anne M. Macgregor‐Das, et al.. (2023). Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19–9 Reference Ranges. Clinical Cancer Research. 29(20). 4178–4185. 16 indexed citations
7.
Fischer, Catherine G., Aparna Pallavajjala, Liqun Jiang, et al.. (2022). Artificial Intelligence-Assisted Serial Analysis of Clinical Cancer Genomics Data Identifies Changing Treatment Recommendations and Therapeutic Targets. Clinical Cancer Research. 28(11). 2361–2372. 10 indexed citations
8.
Craven, Kelly E., Catherine G. Fischer, Liqun Jiang, et al.. (2022). Optimizing Insertion and Deletion Detection Using Next-Generation Sequencing in the Clinical Laboratory. Journal of Molecular Diagnostics. 24(12). 1217–1231. 13 indexed citations
9.
Valle, Blanca L., Elisabetta Kuhn, Teresa Díaz-Montes, et al.. (2020). HIST1H2BB and MAGI2 Methylation and Somatic Mutations as Precision Medicine Biomarkers for Diagnosis and Prognosis of High-grade Serous Ovarian Cancer. Cancer Prevention Research. 13(9). 783–794. 16 indexed citations
10.
Thompson, Elizabeth D., Nicholas J. Roberts, Laura D. Wood, et al.. (2020). The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go. Modern Pathology. 33(12). 2544–2563. 29 indexed citations
11.
Guerrero‐Preston, Rafael, Fahcina Lawson, Maartje Noordhuis, et al.. (2019). JAK3 Variant, Immune Signatures, DNA Methylation, and Social Determinants Linked to Survival Racial Disparities in Head and Neck Cancer Patients. Cancer Prevention Research. 12(4). 255–270. 16 indexed citations
12.
Paller, Channing J., James R. Eshleman, Samuel R. Denmeade, et al.. (2019). A pilot study of prostate‐specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer. The Prostate. 79(14). 1597–1603. 18 indexed citations
13.
Guedes, Liana B., Emmanuel S. Antonarakis, Michael T. Schweizer, et al.. (2017). MSH2 Loss in Primary Prostate Cancer. Clinical Cancer Research. 23(22). 6863–6874. 112 indexed citations
14.
Rodić, Nemanja, Robert A. Anders, James R. Eshleman, et al.. (2014). PD-L1 Expression in Melanocytic Lesions Does Not Correlate with the BRAF V600E Mutation. Cancer Immunology Research. 3(2). 110–115. 42 indexed citations
15.
Kanda, Mitsuro, Spencer Knight, Mark Topazian, et al.. (2012). Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut. 62(7). 1024–1033. 119 indexed citations
16.
Cui, Yunfeng, Jacqueline A. Brosnan‐Cashman, Amanda L. Blackford, et al.. (2012). Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro Chemosensitivity. Clinical Cancer Research. 18(23). 6519–6530. 54 indexed citations
17.
Wang, Qing, Raghothama Chaerkady, Jian Wu, et al.. (2011). Mutant proteins as cancer-specific biomarkers. Proceedings of the National Academy of Sciences. 108(6). 2444–2449. 128 indexed citations
18.
Vincent, Audrey, Noriyuki Omura, Seung‐Mo Hong, et al.. (2011). Genome-Wide Analysis of Promoter Methylation Associated with Gene Expression Profile in Pancreatic Adenocarcinoma. Clinical Cancer Research. 17(13). 4341–4354. 137 indexed citations
19.
Wu, Jian, Hanno Matthaei, Anirban Maitra, et al.. (2011). Recurrent GNAS Mutations Define an Unexpected Pathway for Pancreatic Cyst Development. Science Translational Medicine. 3(92). 92ra66–92ra66. 562 indexed citations breakdown →
20.
Iacobuzio–Donahue, Christine A., Anirban Maitra, Mari Olsen, et al.. (2003). Exploration of Global Gene Expression Patterns in Pancreatic Adenocarcinoma Using cDNA Microarrays. American Journal Of Pathology. 162(4). 1151–1162. 394 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Darryl Shibata Breakdown of academic impact, for papers by David G. Huntsman Breakdown of academic impact, for papers by Michael F. Berger Breakdown of academic impact, for papers by G. Johan A. Offerhaus Breakdown of academic impact, for papers by Jin Jen Breakdown of academic impact, for papers by J. Milburn Jessup Breakdown of academic impact, for papers by Kathleen R. Cho Breakdown of academic impact, for papers by Ann D. Thor Breakdown of academic impact, for papers by Heinz Höfler Breakdown of academic impact, for papers by Manuel Perucho
Rankless by CCL
2026